Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GC6101A
- Development stage
- Phase 2
- Lead developer
- 绿十字
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GC6101A is a botanical drug product derived from the flower of *Lonicera japonica* (commonly known as Japanese honeysuckle or Lonicerae Flos). It has been developed primarily for the treatment of digestive system disorders, with a focus on gastritis. The exact mechanism of action is not specified in available sources, but as a botanical extract, it likely contains multiple bioactive compounds that may exert anti-inflammatory or mucosal protective effects relevant to gastritis. The drug was developed by Green Cross Co., Ltd., and has reached Phase 2 clinical trials in South Korea for gastritis[1][2][3][4].
- Other names
- Lonicera japonicaLonicerae Flos
Beyond the preview
Go deeper on GC6101A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GC6101A.